報價延遲最少15分鐘:2026/07/06 20:43 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.1 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.77/-1.29
|
|
企業價值
127.27M
|
| 資產負債 |
|
每股賬面淨值
-3.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
642.00K
|
|
每股收益
0.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |
